Landos Biopharma, a clinical-stage biopharmaceutical company, has completed a USD60m Series B financing round, it was reported yesterday.

The financing was co-led by RTW Investments and Perceptive Advisors (Perceptive Xontogeny Venture Fund and Perceptive Life Sciences Fund), and joined by additional new investors, including Osage University Partners and PBM Capital.

The financing is intended to support Phase two global clinical trials for the company's lead product, BT-11, in ulcerative colitis and Crohn's disease.